How a White House Push and a Regulatory Shake-Up Opened the Door for a Third FDA Review

 

How a White House Push and a Regulatory Shake-Up Opened the Door for a Third FDA Review

**Subheading:** *After two rejections and a controversial departure at the FDA, a small biotech’s melanoma drug is getting a third look—and its stock surged more than 70%. Here’s the inside story of how politics, patient advocacy and regulatory science collided.*

---

It was the kind of roller‑coaster ride that only a small biotechnology company could deliver—and it left investors, patients and regulators all wondering the same thing: How did a twice‑rejected cancer drug get a third chance at the FDA?

The answer involves a high‑stakes White House meeting, the sudden resignation of the agency’s commissioner, a passionate campaign by melanoma patients, and a debate that cuts to the heart of how we weigh promising science against the gold standard of clinical evidence.

On May 29, 2026, **Replimune Group** announced that it had reached an agreement with the FDA to resubmit its application for RP1, an experimental melanoma treatment that had already been rejected twice [0†L5-L8][2†L4-L8]. The news sent the company’s stock soaring more than 70% in pre‑market trading [2†L10-L12][9†L4-L8].

But the story behind that announcement is far more complicated—and more revealing—than the stock chart suggests.

---

### Two Rejections, One Scientific Sticking Point

Before the third chance, there were two hard “no’s.”

In July 2025, the FDA rejected Replimune’s initial application for RP1, an oncolytic virus therapy designed to infect and kill cancer cells while also triggering a systemic immune response against the tumor [1†L44-L47][9†L4-L6]. The agency’s main objection? The pivotal **IGNYTE trial** was a single‑arm study—meaning every patient received the experimental drug, and there was no control group to compare outcomes against [6†L44-L46].

A second complete response letter arrived on April 10, 2026 [1†L18-L22]. Despite a breakthrough therapy designation and priority review status, the FDA again concluded that the evidence, while promising, did not meet the bar for approval [1†L44-L48].

The numbers from IGNYTE were striking: A **34% response rate** and a median duration of response of **24.8 months**—a meaningful benefit for patients with advanced melanoma who had already progressed on standard immunotherapy [6†L16-L18][5†L34-L36]. But the FDA’s concern was procedural and scientific: without a control arm, it was impossible to know whether the improvements were truly due to RP1 or simply the natural course of the disease.

### Patient Advocates and a High‑Profile Distance

In the weeks that followed the April rejection, the story moved from the lab to the political stage. Health and Human Services Secretary **Robert F. Kennedy Jr.**, a Trump appointee who has long questioned federal health agencies, publicly distanced himself from the FDA’s decision [11†L10-L13].

In late April, Kennedy testified before the Senate that the rejection was not his call—it was FDA Commissioner **Dr. Marty Makary’s** [11†L4-L9]. Yet in the same breath, he expressed “disappointment” with the process and suggested that effective therapies should be made available to desperate patients [11†L26-L31].

Melanoma specialists and patient advocacy groups also weighed in. In the U.S., there are roughly **110,000 new melanoma cases each year**, and about **8,500 people die annually from advanced forms of the disease** [5†L15-L16][7†L8-L9]. For those patients, each month of waiting can feel like a lifetime.

### The White House Push

The political pressure didn’t stop at Capitol Hill. According to people familiar with the matter, Replimune representatives met directly with **White House officials in early May** to argue that the FDA’s repeated rejections didn’t align with the Trump administration’s stated goal of helping terminally ill patients gain faster access to promising therapies [0†L11-L13][4†L9-L13].

The message landed. By the end of the month, the agency’s posture had shifted. Replimune announced a formal agreement on a resubmission path, and the FDA pledged to treat the new application **as an urgent matter** and **prioritize its review** [0†L8-L11][2†L26-L31].

### The Eleventh‑Hour Resignation

A key piece of the puzzle fell into place just before that announcement. On May 12, 2026, **FDA Commissioner Marty Makary resigned** [10†L4-L8]. The surgeon and author had led the agency for just over a year, but his tenure was marked by mounting criticism from industry executives, anti‑abortion activists and vaping lobbyists [10†L31-L35].

Makary’s departure created a leadership vacuum at the FDA, with **Kyle Diamantas**, the chief of foods, stepping in as acting commissioner [10†L20-L24]. But more importantly for Replimune, it opened the door for a new review team—one that might be more willing to re‑examine the RP1 data [6†L37-L39].

Indeed, one of the company’s sharpest critiques of the April rejection was that the second review was conducted by a **completely new team that had never worked on the program before** [6†L29-L31]. That team, Replimune argued, appeared to contradict positions the agency had taken in earlier meetings [6†L37-L39][7†L15-L16].

### The Debate That Refuses to Die

At its core, the RP1 dispute is about a fundamental question in modern medicine: **How much evidence is enough before you give a drug to dying patients?**

Replimune points to the compelling response rates and survival data from IGNYTE, and to the March 2021 meeting minutes where the FDA suggested a single‑arm trial could be acceptable for accelerated approval [13†L4-L10]. The agency also acknowledged after expert testimony that randomizing patients to an anti‑PD‑1 only arm might not be feasible [6†L15-L18].

The FDA, for its part, has consistently held that the company had opportunities to design a cleaner, more interpretable trial but chose not to [5†L42-L48]. By the time of the second rejection, the agency’s position had hardened: it “would not recommend” seeking approval based solely on a single‑arm study [13†L16-L19].

### What the Third Chance Actually Means

It’s important to be clear about what the May 29 announcement did—and did not—do.

The FDA agreed to a **resubmission pathway**, and it will treat the new application with **priority review** [4†L40-L43]. That is a genuine procedural win for Replimune, and it’s why the stock surged.

But the scientific question has not changed. The IGNYTE data remain the same. The absence of a control arm remains a concern [3†L40-L41]. The agency has not endorsed the drug; it has simply agreed to look at the package again, with fresh eyes and under a different leadership.

Investors and patients should also note that Replimune is still a clinical‑stage company with **zero revenue** and a market cap of roughly $390 million [3†L41-L42][8†L27-L28]. Nearly every dollar of that valuation is **option value**—a bet on whether RP1 will eventually cross the finish line [3†L42-L44].

### What Comes Next

Replimune has said it will file its new application “in the coming days” [4†L39-L40]. The FDA has not set a new PDUFA date, but the priority review designation suggests a decision could come within six to eight months, rather than the standard ten to twelve.

In the meantime, the company will continue to rely on the IGNYTE data, while hoping that the new review team—and the weight of White House and HHS attention—will lead to a different outcome.

For patients and families affected by advanced melanoma, the stakes are existential. For Replimune, they are financial. And for the FDA, the case has become a flashpoint in a larger debate about regulatory consistency, accelerated approval pathways, and the tension between scientific rigor and compassionate access.

---

## Frequently Asked Questions (FAQ)

**Q1: Was the drug RP1 approved?**

No. The FDA agreed to accept a **resubmission** of the application and to prioritize its review. Approval is not guaranteed.

**Q2: Why did the FDA reject RP1 twice?**

Both rejections centered on the same issue: the pivotal IGNYTE trial was a **single‑arm study**, with no control group. The FDA concluded that the evidence did not meet its standard for approval.

**Q3: How did the White House get involved?**

Replimune representatives met with White House officials in early May, arguing that the FDA’s rejection conflicted with the administration’s goal of helping terminally ill patients access promising therapies. The White House then pushed health officials to re‑examine the case.

**Q4: Did the FDA commissioner resign because of RP1?**

Not solely. Commissioner Marty Makary resigned after a rocky tenure marked by broader conflicts with health industry executives and political allies of the administration. However, the RP1 controversy was widely seen as a flashpoint in the tensions that led to his departure.

**Q5: Is RP1 safe?**

In the IGNYTE trial, RP1 plus nivolumab showed a **favorable safety profile** with no unexpected safety signals. Side effects were generally manageable, though specific rates were not detailed in the public summary.

**Q6: Has the science changed since the second rejection?**

The underlying IGNYTE data are unchanged. The **trial design remains the same**. What has changed is the leadership at the FDA and the political pressure to take another look.

**Q7: What does “priority review” mean?**

Priority review is a designation that shortens the FDA’s review clock from ten months to about six months. It does not imply that the drug will be approved.

**Q8: When will we know the outcome?**

The FDA has not set a new target date, but with priority review, a decision could come within six to eight months of the resubmission.

**Q9: Is Replimune a public company?**

Yes. Replimune trades on the Nasdaq under the ticker **REPL**.

**Q10: What’s the biggest risk for investors now?**

The biggest risk is the same as before the third chance: the FDA could again determine that the single‑arm trial design does not provide sufficient evidence of effectiveness, leading to a third rejection—and a likely collapse in the stock price.

---

*Disclaimer: This article is for informational and educational purposes only and does not constitute financial or medical advice. Biotech stocks are highly volatile, and regulatory outcomes are inherently uncertain. Please consult with a qualified financial advisor before making investment decisions, and talk to your doctor about any medical treatment.*